Coronavirus vaccination

Acceptability at Recruitment Qualified

Acceptability at CT/Workup Qualified

Guidance

Obligatory

a) UK vaccination programme (Recipients of the Pfizer/BioNTech Covid-19 vaccine or the AstraZeneca COVID-19 vaccine)

Must not donate if;

i) Less than seven days after the most recent vaccination was given (to start of G-CSF)

ii) If donor felt unwell after vaccination, must not donate for 7 days after the resolution of symptoms.

b) Recipients of any other Covid-19 vaccine, including participants in clinical trials or donors vaccinated outside the UK.

Refer to Medical Officer for individual risk assessment. See Additional information.

Discretionary

Donors may be accepted less than 7 days after the date of the most recent vaccination if vaccinated as part of the UK vaccination programme, subject to individual risk assessment. See additional information.

See if relevant Coronavirus Infection

Additional Information

Individuals vaccinated with inactivated viruses of vaccines that do not contain live agents (ie. mRNA and protein subunit vaccines) may be accepted as tissue and cell donors if they feel well after vaccination. After vaccination with attenuated viruses (e.g. virus vector based other than non-replicated or live-attenuated virus vaccines) tissue and cell donors must be deferred for four weeks.

Both the Pfizer/BioNTech Covid-19 vaccine and the AstraZeneca COVID-19 vaccine (both currently available in the UK) are non-live. However as the effects of the newly developed coronavirus vaccines on donor health and donation safety are not fully established yet, as a precautionary principle a 7 day deferral from the date of vaccination, or deferral of donors who developed symptoms directly related to the vaccine for at least 7 days after the resolution of symptoms, is recommended. Donors within 7 days after non-live vaccine, may be considered subject to individual risk assessment, if the benefit of the transplant outweighs the risk of donation.

For donors vaccinated as part of a clinical trial or outside of the UK, the type of vaccine used should be established to determine the appropriate deferral period.

There may be new types of vaccine that become available, and it may not be known which type of vaccine was used for immunization. In situation where information about vaccine type is missing or the vaccination is experimental, a four week deferral period should be applied.

The ECDC recommends that if HSC donors have been vaccinated with attenuated vaccines int eh four weeks before donation, a risk assessment should be carried out and taken into account when deciding on transplantation, and if transplanted, the recipient should be monitored post-transplant.

Disease Protected against	Comments and examples of trade names/preparations	Header text
COVID019 (SARS-CoV-2)	Pfizer/BioNTech COVID-19 vaccine. AstraZeneca Covid-19 vaccine.	Non-live
Example	Example	Example